V5 Ultimate
Ultimate
PricingResourcesCompany
English (original)العربيةDeutschΕλληνικάEspañolFrançaisItalianoעברית日本語한국어NederlandsPolskiPortuguêsSvenska
Talk to us Log in Start free trial
Food & Beverage
  • Bakery & Confectionery
  • Food Processing
  • Ingredients & Dry Mixes
  • Sausage & Meat Products
  • Produce Packing
  • Pet Food & Pet Supplements
  • Dairy & Chilled Foods
  • Beverages & Liquid Manufacturing
  • Infant Formula
Pharma & Life Sciences
  • Radiopharmaceuticals
  • Pharmaceutical
  • Medical Devices
  • Veterinary Pharmaceuticals
  • Blood & Tissue
  • Diagnostics & IVD Kits
  • Reference Materials & Standards
  • OTC Topical Creams & Gels
Supplements & Personal Care
  • Dietary Supplements
  • Cosmetics & Personal Care
  • Cannabis & Hemp Manufacturing
  • Fragrances & Perfumery
  • Soaps & Personal Hygiene
  • Botanical Extracts & Essential Oils
Chemicals & Materials
  • Plastics & Resins
  • Agricultural Chemicals
  • Specialty & Industrial Chemicals
  • Printing Inks, Pigments & Construction Chemicals
  • Lubricants & Metalworking Fluids
  • Coatings, Adhesives & Sealants
Other Manufacturing
  • Consumer Products
  • Electronics & Electrical Assembly
  • Textiles & Nonwoven
  • Contract Manufacturing & Co-Packing
  • Packaging & Food-Contact Materials
  • Regulated Warehousing & Distribution
Explore all industries
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Why V5? Product & Features
Why V5?Product & Features
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Explore all industries
    • Bakery & Confectionery
    • Food Processing
    • Ingredients & Dry Mixes
    • Sausage & Meat Products
    • Produce Packing
    • Pet Food & Pet Supplements
    • Dairy & Chilled Foods
    • Beverages & Liquid Manufacturing
    • Infant Formula
    • Radiopharmaceuticals
    • Pharmaceutical
    • Medical Devices
    • Veterinary Pharmaceuticals
    • Blood & Tissue
    • Diagnostics & IVD Kits
    • Reference Materials & Standards
    • OTC Topical Creams & Gels
    • Dietary Supplements
    • Cosmetics & Personal Care
    • Cannabis & Hemp Manufacturing
    • Fragrances & Perfumery
    • Soaps & Personal Hygiene
    • Botanical Extracts & Essential Oils
    • Plastics & Resins
    • Agricultural Chemicals
    • Specialty & Industrial Chemicals
    • Printing Inks, Pigments & Construction Chemicals
    • Lubricants & Metalworking Fluids
    • Coatings, Adhesives & Sealants
    • Consumer Products
    • Electronics & Electrical Assembly
    • Textiles & Nonwoven
    • Contract Manufacturing & Co-Packing
    • Packaging & Food-Contact Materials
    • Regulated Warehousing & Distribution
PricingResourcesCompany
Start free trial Log in Talk to us
HomeGlossaryCritical Material Attribute
Quality · The complete guide

Critical Material Attribute (CMA): Definition and Control

In short

Connect material variability to product quality through clear definitions, justified controls, worked examples and traceable decisions.

4,009 words · ~19 min read
A formulation scientist in hair cover, mask and gloves reviews a particle size distribution beside a laser diffraction analyzer
A critical material attribute such as particle size is a property of an input material that must be controlled to protect product quality.
On this page
  1. 01What a Critical Material Attribute is—and what it is not
  2. 02Where guidance, law and cross-sector practice differ
  3. 03Identify CMAs by tracing product-quality risks upstream
  4. 04Three worked cases: particle size, assay and moisture
  5. 05Turn study evidence into measurable acceptance criteria
  6. 06Apply CMA controls at receiving and lot disposition
  7. 07Use process monitoring without overstating what it proves
  8. 08Connect material data and recover safely from interface failures
  9. 09Reassess CMAs when materials, methods or processes change
  10. 10Keep the evidence chain from attribute rationale to batch use
  11. 11Check implementation gaps before relying on the controls
  12. 12How V5 Ultimate supports the batch-evidence review
On this page · 12 sections
  1. 1What a Critical Material Attribute is—and what it is not
  2. 2Where guidance, law and cross-sector practice differ
  3. 3Identify CMAs by tracing product-quality risks upstream
  4. 4Three worked cases: particle size, assay and moisture
  5. 5Turn study evidence into measurable acceptance criteria
  6. 6Apply CMA controls at receiving and lot disposition
  7. 7Use process monitoring without overstating what it proves
  8. 8Connect material data and recover safely from interface failures
  9. 9Reassess CMAs when materials, methods or processes change
  10. 10Keep the evidence chain from attribute rationale to batch use
  11. 11Check implementation gaps before relying on the controls
  12. 12How V5 Ultimate supports the batch-evidence review
AI · Explain it for MY operation

How does Critical Material Attribute apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your scale

01What a Critical Material Attribute is—and what it is not

Critical Material Attribute (CMA) is a physical, chemical, biological, or microbiological property of an input material whose variability can affect a downstream product’s critical quality attributes and therefore needs appropriate control. This is an operational pharmaceutical-development definition, not a quoted legal definition. It focuses attention on what the material brings into a process and how variation in that property could affect the resulting product.

Material attribute is the broader term. An attribute is not critical merely because it appears on a specification, is routinely reported by a supplier, or is easy to measure. Criticality concerns its effect in a particular product and process. Supplier identity and lot number help establish traceability; they are not themselves physical, chemical, biological, or microbiological properties of the material.

TermWhat it describesExampleImportant boundary
CMAInput-material propertyDrug-substance particle sizeCriticality depends on downstream impact.
CQAQuality property of the material or product under considerationTablet dissolutionCan also describe an upstream material; see ICH Q8(R2), Annex glossary: CQA.
CPPProcess variable whose variability affects a CQACompression force, where its quality impact makes it criticalAn operating condition rather than a material property; see ICH Q8(R2), Annex glossary: CPP.
Material specificationDocumented acceptance rulesParticle-size limit and methodNot the same thing as a criticality rationale.

The CQA and CPP definitions above come from ICH pharmaceutical-development guidance. A critical quality attribute describes a quality property that should remain within an appropriate limit, range, or distribution. A critical process parameter identifies a process variable that needs monitoring or control because its variability affects a CQA. Neither label means that every measured property or recorded machine setting is critical.

The upstream/downstream distinction is a matter of perspective, not a contradiction. Particle size can be a drug-substance CQA and serve as a CMA in the subsequent drug-product process. ICH Q8(R2), Annex 2.2 explicitly includes properties such as particle-size distribution and bulk density among upstream-material CQAs that can affect drug-product CQAs.

In practical documentation, name the material, the property, and the downstream quality concern rather than writing only “critical raw material.” That makes the proposed relationship understandable without treating the entire purchasing record as a scientific attribute. The next step is linking material attributes to product quality.

02Where guidance, law and cross-sector practice differ

Use the CMA concept within the right product and jurisdictional context. A pharmaceutical-development framework can help structure engineering questions elsewhere, but transferring that reasoning does not transfer its regulatory status.

ContextProduct or jurisdictionAuthority typeAppropriate use
ICH Q8(R2)Pharmaceutical developmentGuidanceExplain product and process understanding through the control-strategy discussion.
FDA process-validation guidanceUS FDA pharmaceutical contextNonbinding guidanceEvaluate variability across the lifecycle.
21 CFR 211.84US regulatory scope checkBinding regulation when applicableCheck its current applicability and requirements.
Food, supplements, devices and chemicalsSector-specific contextsIndustry-practice analogy onlyEstablish applicable requirements separately.

ICH Q8(R2), Annex 2.5 discusses describing and justifying control-strategy elements in pharmaceutical development. Use that discussion to organise the scientific rationale within quality by design, not as evidence of automatic legal adoption in a jurisdiction.

The FDA process-validation recommendations, Section IV, are nonbinding guidance. They support a variability-focused approach to process validation. Check the current text of 21 CFR 211.84 for applicability and requirements.

As conditional engineering examples, powder moisture could affect supplement processing; ingredient functionality could affect food texture; resin viscosity could affect device-component mould filling; and feedstock impurity could affect chemical reaction performance. None is automatically a CMA without a product/process rationale. For each, identify the quality outcome at risk, the proposed material-to-quality relationship and the evidence needed to test it. The worked cases below demonstrate that reasoning without turning these analogies into sector-specific regulatory rules.

03Identify CMAs by tracing product-quality risks upstream

Start with intended product performance and potential CQAs, then trace plausible sources of variation upstream to materials and processing. ICH Q8(R2), Annex 2.2 describes potential product CQAs derived from the quality target product profile or prior knowledge as guides to development. For terminology, use the CMA, CQA and CPP comparison.

As a practical identification method, build one evidence chain per candidate attribute:

  • Attribute: identify the measured material property and its variability across representative lots; supplier names are not substitutes for measurements.
  • Mechanism: identify the affected CQA, expected direction of effect and process conditions under which the relationship is plausible.
  • Evidence: record study results, remaining uncertainty and a proposed control justified by the current understanding.

ICH Q8(R2), Annex 2.4.1 explains that risk assessment and development experiments can establish understanding of material/process links to product CQAs. Operationally, label an untested mechanism as a hypothesis, not a demonstrated effect. Screening correlations help prioritize investigations but may reflect confounding: a material property and a process setting might have changed together.

Investigate material effects and interactions using representative lots, controlled or recorded process conditions, suitable measurement methods and replication proportionate to uncertainty. Record both the range studied and the conditions held constant. A narrow development range leaves uncertainty outside that range; absence of an observed effect does not establish independence.

Q8 Annex 2.4.1 recommends highlighting attributes and parameters not varied during development. Separately, Annex 2.4.6 says determining the edge of failure or demonstrating failure modes is not essential to establishing a process design space. Do not confuse an unexplored range with a requirement to force failure.

FDA process-validation guidance, IV.A describes criticality as a continuum rather than a binary state and recommends control commensurate with risk to the process and its output. These are guidance recommendations, not standalone legal requirements.

Operational Lifecycle

Intended performance → potential CQAs → material/process hypotheses → studies → uncertainty assessment → proposed controls → routine evidence → reassessment. Use this practical lifecycle map to connect investigation outcomes to the control strategy, returning to the hypothesis when new evidence challenges the relationship.

CMA Identification and Control Lifecycle
  1. 1
    Set quality objectivesIdentify intended performance and relevant product CQAs.
  2. 2
    Map material risksConnect candidate attributes to plausible quality effects.
  3. 3
    Test relationshipsStudy variability, process interactions and measurement limitations.
  4. 4
    Define controlsDocument methods, acceptance rules and permitted responses.
  5. 5
    Assess material lotsEvaluate results and resolve exceptions before use.
  6. 6
    Connect batch evidenceLink consumed lots with process and quality observations.
  7. 7
    Review and reviseReassess evidence when trends or changes emerge.
A practice-based workflow connecting material variability, product quality and reviewed control decisions.

04Three worked cases: particle size, assay and moisture

All three cases use illustrative assumptions for pharmaceutical manufacturing. They are not operating specifications or reported study outcomes. Their purpose is to show how material measurements inform decisions—and where arithmetic or a small comparison stops short of a justified control.

Case 1: Particle size and dissolution

Assume fixed formulation and process settings, with volume-based particle-size D90 values of 60, 90 and 120 µm. D90 is the diameter below which 90% of the measured particle volume falls. Assume measured dissolution at 30 minutes is 94%, 88% and 79%, respectively, against an illustrative criterion of at least 85%.

D90Dissolution at 30 minutesMargin to assumed criterion
60 µm94%+9 percentage points
90 µm88%+3 percentage points
120 µm79%−6 percentage points

Each margin subtracts 85% from the dissolution result. These are percentage-point differences, not percentage changes relative to a baseline. The pattern supports further investigation of particle size as a candidate CMA, but does not establish 90 µm as a universally safe upper limit. Replication, method performance, intermediate particle sizes and process interactions remain relevant before adopting a particle-size gate. D90 also does not describe the entire particle-size distribution.

Case 2: Assay and dispensing quantity

Assume a two-component, 100.0 kg mixture requiring 24.0 kg of active constituent. The active-containing raw material has an assay of 96.0% w/w on an as-is basis; the carrier contributes no active constituent. Assume no material loss.

  • Required raw material: 24.0 kg ÷ 0.960 = 25.0 kg.
  • Carrier balance: 100.0 kg − 25.0 kg = 75.0 kg.
  • Adding only 24.0 kg of raw material supplies 24.0 kg × 0.960 = 23.04 kg of active constituent.
  • Shortfall: 24.0 kg − 23.04 kg = 0.96 kg, or 0.96 ÷ 24.0 × 100 = 4.0% of the target.

Measured assay characterises the input; the product-strength objective sets the active target; the dispensing calculation translates those values into mass. This arithmetic does not itself authorise potency adjustment, changes to other ingredients or substitution between dry-basis and as-is results. Such adjustments need a justified, reviewed formulation and process instruction.

Case 3: Moisture–compression interaction

Assume incoming granule moisture of 1.0% or 3.0% w/w, compression force of 8 or 12 kN, and an illustrative tablet-friability criterion of no more than 1.0% mass loss.

MoistureCompression forceFriabilityResult
1.0%8 kN1.3%fails
1.0%12 kN0.8%passes
3.0%8 kN0.7%passes
3.0%12 kN0.6%passes

Moisture is the material input, compression force the process setting, and friability the measured product outcome. Raising force reduces assumed friability by 0.5 percentage points at 1.0% moisture, but only 0.1 at 3.0% moisture—suggesting an interaction worth investigating. These four hypothetical combinations neither establish a design space nor authorise unrestricted compensation through compression force. Other quality outcomes remain untested; see turning evidence into acceptance criteria.

05Turn study evidence into measurable acceptance criteria

As an operational practice, keep four control-document functions distinct:

  • Criticality rationale: explains how attribute variability can affect product quality and records the supporting evidence.
  • Routine material acceptance rule: states how a result determines suitability for a specified use.
  • Investigation trigger: identifies a result, trend or discrepancy needing review, potentially before an acceptance limit is exceeded.
  • Broader control strategy: coordinates material controls with processing, monitoring and quality decisions.

ICH Q8(R2), Annex glossary: Control Strategy describes a planned set of controls derived from product and process understanding. This pharmaceutical guidance concept is broader than a numerical limit: the operational control strategy should explain how sampling, measurement, processing and decisions work together.

For a reproducible acceptance rule, specify:

  • Material and attribute identifiers; applicable grade or intended use.
  • Sampling basis; analytical method and version.
  • Reported statistic, units and result basis, such as dry basis or as received.
  • Acceptance limits and rounding convention.
  • Effective specification version and decision owner.

Specify the statistic precisely. Particle-size D90 is a percentile—the diameter at or below which 90% of the stated distribution falls—not a mean. Identify whether that distribution is volume-, mass- or number-based.

Treat guard bands and measurement uncertainty as product- and method-specific decisions, not mandatory fixed percentages. A development range explores behaviour; a purchasing tolerance defines routine supply expectations and may be narrower. Document the reason for any difference. Where criticality remains uncertain, retain a documented provisional control, its justification, decision owner and review trigger rather than inventing an unsupported limit.

An acceptance interval is not itself a demonstrated process design space. ICH Q8(R2), Annex glossary: Design Space defines a multidimensional combination and interaction of inputs and process parameters demonstrated to assure quality. Preserve that distinction when translating study conclusions into receiving and lot-decision controls.

06Apply CMA controls at receiving and lot disposition

An example site procedure starts by identifying the received lot and establishing its initial status. Select the applicable specification, obtain a representative sample with documented chain of custody, record results, assess exceptions and document an authorized lot-use decision. Set sample counts and test panels for the material and intended use—not universally.

Design sampling around particle segregation, moisture uptake during handling and container-to-container differences. A composite sample may conceal variability relevant to a downstream process; consider whether separate container or location results are needed before combining samples.

Treat a supplier certificate as an attributed data source: retain supplier lot identity, reported method, units, result basis and document version. Distinguish missing information from an invalid or disputed result, and from a result outside the applicable acceptance rule. Record the investigation and decision rationale; another passing test does not, by itself, resolve the original exception.

Approved, restricted-use, pending and rejected are possible local workflow statuses, not universal regulatory vocabulary. Define their permissions within applicable constraints and keep material-lot disposition separate from finished-product release. For legal applicability, use the product and jurisdiction scope map.

What if two laboratories disagree?

Within the receiving and disposition workflow, compare sample identity, preparation, units, result basis, method versions and method suitability before choosing an investigation path. Consider both measurement disagreement and genuine material heterogeneity without assuming either laboratory is correct.

07Use process monitoring without overstating what it proves

ICH Q8(R2), Annex 2.5 describes an adaptive process step as one control-strategy option. Material variability can sometimes be managed by a responsive step when the input–response relationship is understood and appropriate controls ensure consistent product quality.

  • Direct measurement: an at-line moisture test measures the sampled material’s moisture, not necessarily the whole lot.
  • Correlated surrogate: a model-based material-property estimate, such as a soft-sensor prediction, depends on demonstrated relationships rather than direct measurement.
  • Process signal: dryer exhaust temperature describes a process condition; it is not automatically a CMA measurement.

For practical monitoring, define measurement timing, sampling location, calibration or model maintenance, and the applicable material range. Outside that range, flag results as unsupported for adjustment decisions and route them for assessment. Connect drift and model maintenance to lifecycle review and change control. A downstream signal alone does not justify deleting an incoming control or expanding adjustment limits.

Can conforming lots simply be blended?

Not on constituent acceptance alone. An average can conceal a broad or uneven attribute distribution, and segregation can alter local composition. Assess the actual blend and intended process, including mixing behaviour and relevant sampling. No universal weighted-average acceptance rule establishes suitability.

08Connect material data and recover safely from interface failures

A practical architecture separates responsibilities without mandating particular system types or claiming integration-standard conformance. Purchasing or inventory records identify materials and lots; laboratory records hold samples, methods and results; execution records identify lots actually consumed; quality records hold review outcomes and exceptions. These responsibilities can share a platform or span connected applications.

For a laboratory-to-execution handoff, define a minimal payload: material_lot_id, attribute_id, method_version, result_value, result_unit, result_basis, specification_version, decision_status, event_id and effective_at. Specify whether result_basis means, for example, dry basis or as received, and what effective_at timestamps. Map supplier lot identifiers to internal identifiers: supplier numbering may overlap across suppliers, while one received lot may have several internal stock records.

  • Detect duplicate messages using event_id; replay must not create duplicate decisions.
  • Route unrecognised units, stale specification versions and missing lot mappings to an exception queue rather than silently substituting values.
  • Link corrected results to the superseded result; retain both and the correction reason.
  • During temporary connection loss, queue events for retry and keep unresolved status pending. A missing result is not a passing result.

For controlled recovery, retain the exception, assign a responsible owner, resolve the mapping or data issue, then replay and reconcile the resulting status between sender and receiver. Preserve the resolution reason alongside the event history. Connect these exchanges to the CMA evidence and record relationships.

09Reassess CMAs when materials, methods or processes change

For pharmaceutical process validation, FDA process-validation guidance, IV.A recommends evaluating attributes and parameters by their process roles and impact on product or in-process material, then reevaluating them as new information becomes available. This is a guidance recommendation, not a standalone legal requirement.

As an operational practice, initiate a product-specific CMA review through change control for supplier manufacturing-route changes, grade changes, shifts in particle-size distribution, a new analytical method, scale or equipment changes, or a revised formulation. Recurring deviations and drift within acceptance limits also warrant review. Identical supplier specification wording does not establish equivalent variability or processing behaviour.

Use the evidence-led approach described in the identification section to distinguish three review outcomes:

  • Retain the CMA classification and existing controls.
  • Change the control approach while retaining the scientific rationale for criticality.
  • Revise the criticality judgement when new evidence supports that conclusion.

Stable results under a strong control do not alone establish that the attribute is unimportant: the control may be preventing the harmful variation.

Record affected products, supporting evidence, remaining uncertainty, implementation conditions and effective versions of the rationale and controls. Make the decision traceable to the applicable material, method and process configuration. Before implementation, use the implementation and review checklist to check execution readiness.

10Keep the evidence chain from attribute rationale to batch use

Use these five linked record groups as a suggested data model, not as a description of a particular application:

  1. CMA rationale: the attribute, affected product-quality outcome, scientific justification and links to supporting study evidence.
  2. Material specification: acceptance criteria and the specification version effective when the lot was assessed, distinguished from the current version.
  3. Lot test: material and lot identifiers, sample identity, result, result basis, units and method version.
  4. Batch usage: the material lot, consuming batch and quantity consumed.
  5. Review decision: disposition, reviewer, date, rationale and links to the evidence considered.

One material lot can supply several batches, and one batch can consume several lots. The consumption link is therefore necessary for useful downstream impact assessment. Corrections should leave the earlier decision reconstructable rather than silently replacing its context—a practical data-integrity principle. Carry these identifiers through data handoffs and exception recovery.

Within its pharmaceutical process-validation context, FDA process-validation guidance, IV.A recommends project management and archiving that capture scientific knowledge to improve program effectiveness and efficiency. This is nonbinding guidance, not a mandated database structure.

Evidence Behind a CMA Decision

CMA Rationale

Connects the material attribute to quality evidence.

  • cma_id
  • material_id
  • attribute_id
  • cqa_id
  • evidence_id

Material Specification

Defines the applicable measurement and acceptance rule.

  • specification_version
  • attribute_id
  • method_version
  • result_basis
  • acceptance_rule

Lot Test

Records the sample and measured result.

  • material_lot_id
  • sample_id
  • result_value
  • result_unit
  • specification_version

Batch Usage

Identifies where each lot was consumed.

  • batch_id
  • material_lot_id
  • operation_id
  • quantity_used
  • quantity_unit

Review decision

Records the decision, reviewer and timing.

  • review_id
  • record_id
  • review_outcome
  • reviewer_id
  • reviewed_at
An implementation-neutral model connecting rationale, specifications, measurements, material use and review.

11Check implementation gaps before relying on the controls

Use this practical checklist before relying on CMA controls in routine production. Answer each question by locating the named artifact, not by confirming that a procedure exists.

  • Is the affected CQA named? Check the rationale record.
  • Are the material-to-quality mechanism and supporting evidence linked? Follow the study reference.
  • Are untested conditions visible? Inspect the applicability statement.
  • Does sampling address the attribute’s distribution? Examine the sampling instruction.
  • Are method, units and result basis unambiguous? Inspect the method definition, including relevant measurement and surrogate controls.
  • Is the correct specification version available at the decision point? Retrieve the versioned acceptance rule.
  • Can actual lot consumption be reconstructed? Reconcile the consumption record with batch execution history.
  • Are exceptions assigned and recoverable? Check ownership, recovery steps and closure evidence in the exception record.
  • Is a review trigger and owner defined? Check the review schedule.
GapConsequenceControl check
Unit or result-basis mismatchWrong acceptance decisionExplicit unit and basis checks
Obsolete specification at point of useInconsistent dispositionEffective-version reconciliation
Missing consumption linkIncomplete impact assessmentLot-to-batch reconciliation

12How V5 Ultimate supports the batch-evidence review

Software Support

The V5 Ultimate batch record includes lab samples, QC check results, equipment used, checklists, electronic signatures and deviations. These records can support review alongside the CMA rationale and acceptance criteria.

Human reviewers retain approval and batch release authority; record assembly supports their assessment rather than replacing it.

Does a complete batch record prove CMA controls are adequate?

No. Completeness of the batch evidence used in the review does not establish that the measured attributes, acceptance rules and product-quality rationale are scientifically adequate. Reviewers must assess that justification separately.

Frequently asked questions

Q.Can the same material attribute be critical for one formulation but not another?+

Yes. In practical CMA assessment, criticality depends on the material’s function, formulation and processing conditions—not just its name. Particle size might affect dissolution when a poorly soluble drug remains as solid particles, but have little relevance to dissolution when that drug is fully dissolved during manufacture. Document the mechanism connecting the attribute to a particular critical quality attribute, then test that relationship across relevant material variability. Do not transfer a CMA designation between formulations without reassessing its basis.

Q.Does every field on a supplier certificate of analysis need a CMA designation?+

No. A supplier certificate reports selected characteristics; it is not itself a product-specific criticality assessment. As an operational practice, distinguish attributes linked to product quality from identity information, descriptive fields and other acceptance criteria. Conversely, an attribute important to your formulation may be absent from the certificate. Use supplier risk management to identify those gaps and agree how relevant information will be obtained. A field’s lack of CMA designation is not a reason to disregard an established acceptance criterion.

Q.How should a suspected CMA be managed when development data are too limited to justify a numerical limit?+

Treat it as a potential CMA with explicit uncertainty, rather than inventing a precise acceptance limit. A practical interim approach is to restrict use to characterized material sources and conditions, increase relevant monitoring, and define who reviews unexpected results. Record the suspected failure mechanism and a study plan that challenges meaningful attribute variation. The interim control strategy should identify decision criteria and review triggers; a historical minimum and maximum alone do not establish a scientifically justified operating boundary.

Q.Can two individually conforming material lots become unsuitable when they are blended?+

Yes, although blending does not automatically make acceptable lots unsuitable. Assuming additive masses, no moisture exchange and a common measurement basis, a blend’s average moisture must lie between the two lot values. Other properties need not behave as simple averages: mixing different particle populations can change segregation or packing behavior. As a practical assessment, examine compatibility, distribution and the intended use of the combined material. Stratified blend sampling can help examine spatial variation that a composite average could conceal.

Q.What should be checked when two laboratories disagree about the same material attribute?+

First establish whether the laboratories measured the same property on comparable samples. Check sampling location, sample preparation, storage, elapsed time, method version, calibration, units and reporting basis—for example, as-received versus dry-basis results. Then compare method precision and measurement uncertainty before interpreting the difference as material variability. Use chain of custody records to reconstruct sample handling. As investigative practice, retain both results and resolve their causes; do not simply average them or select whichever supports acceptance.

Q.Does a supplier change need investigation if the material specification stays unchanged?+

An unchanged specification does not establish that the material is unchanged in every relevant respect. As a practical distinction, assess a planned supplier change through change control; an unexplained discrepancy may also warrant an investigation. Compare manufacturing route, source materials, impurity patterns, physical form and handling conditions where relevant to the suspected CMA. Choose comparative testing or manufacturing studies according to the plausible impact. Matching certificate results alone may miss a characteristic that the specification does not measure.

Q.What happens when a material result is corrected after the lot has already been used?+

Preserve the original result, correction, reason and authorization, then reassess the decisions that relied on the earlier value. As practical incident handling, use lot genealogy to identify affected blends, intermediates and finished batches, including their distribution status. Evaluate the corrected value against the applicable acceptance criteria and its potential quality impact. Quality personnel should determine containment and disposition, escalating distributed-product concerns promptly. Even a correction that remains within limits can affect trend interpretation or a calculation used during manufacture.

Q.Does a complete batch record demonstrate that every CMA is adequately controlled?+

No. Completeness demonstrates documentation coverage, not whether the selected controls address the relevant material risks. ICH Q8(R2), Annex section 4 describes a control strategy as derived from current product and process understanding. In practical review, ask whether important attributes were identified, measurements were suitable, sampling captured relevant variability, and controls remained effective. An electronic batch record can organize recorded evidence, but reviewers still need a scientific basis for concluding that material-related risks were adequately controlled.

Primary sources

  • ICH Q8(R2) Pharmaceutical Development
  • FDA Process Validation: General Principles and Practices (2011)
Software that covers Critical Material Attribute
V5 Ultimate (GMP)
V5 Ultimate is a full-lifecycle GMP platform for US and international manufacturers — cGMP under 21 CFR 210/211, EU GMP Parts…
Talk to us about Critical Material Attribute

Want to see how Critical Material Attribute could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.

Start free
Back to glossary
Where this term comes up
PharmaceuticalMedical DevicesDietary SupplementsFood ProcessingCosmeticsChemicals
Inside V5
  • → eBMR / eDHR — the batch record fills in as the work is done.
  • → 21 CFR Part 11 — signatures and audit history your team can validate.
Example reports
V5Ultimate

Sample report

Electronic Batch Manufacturing Record (eBMR)

Plan & make

Electronic Batch Manufacturing Record (eBMR)View on screen or print
V5Ultimate

Sample report

Electronic Device History Record (eDHR)

Plan & make

Electronic Device History Record (eDHR)View on screen or print
V5Ultimate

Sample report

Compliance Readiness Assessment

Quality system

Compliance Readiness AssessmentView on screen or print
V5Ultimate

Sample report

Validation Support Pack

Quality system

Validation Support PackView on screen or print
→ All example reports
Regulatory anchors
  • 21 CFR 211.84
  • 21 CFR 211.110
  • ICH Q8(R2)
  • ICH Q11
Related terms
  • → QbD
  • → ICH Q11
  • → ICH Q9
  • → Excipient
  • → Supplier Qualification

Next Step

Try V5 with your own records, or ask a question first. Ask V5 opens with an editable question; nothing is sent until you choose to.

Start your free trial Browse All Features

Showing the site for the United States. Local spelling, dates and prices are applied automatically; change the language at the top of the page.

V5 Ultimate
Ultimate

Warehouse, quality and manufacturing software for regulated operations.

ProductIndustriesPricingResourcesSecurity & TrustCompanyLegal Centre

© S.G. Systems, LLC